MYNZ Fundamental Analysis - MAINZ BIOMED NV

Fundamental Rating

MYNZ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. MYNZ has a bad profitability rating. Also its financial health evaluation is rather negative. MYNZ is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MYNZ has reported negative net income.

In the past year MYNZ has reported a negative cash flow from operations.

In the past 5 years MYNZ always reported negative net income.

In the past 5 years MYNZ always reported negative operating cash flow.

1.2 Ratios

MYNZ's Return On Assets of -220.85% is on the low side compared to the rest of the industry. MYNZ is outperformed by 91.15% of its industry peers.

Looking at the Return On Equity, with a value of -858.34%, MYNZ is doing worse than 79.85% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-220.85%
ROE	-858.34%
ROIC	N/A

ROA(3y)-154.86%

ROA(5y)-133.82%

ROE(3y)-451.51%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 64.31%, MYNZ is doing good in the industry, outperforming 79.85% of the companies in the same industry.

MYNZ's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for MYNZ so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	64.31%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y27.49%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MYNZ has been increased compared to 1 year ago.

MYNZ has more shares outstanding than it did 5 years ago.

The debt/assets ratio for MYNZ has been reduced compared to a year ago.

2.2 Solvency

MYNZ has an Altman-Z score of -16.29. This is a bad value and indicates that MYNZ is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -16.29, MYNZ is not doing good in the industry: 82.11% of the companies in the same industry are doing better.

MYNZ has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of MYNZ (0.44) is worse than 71.56% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF	N/A
Altman-Z	-16.29

ROIC/WACCN/A

WACC6.07%

2.3 Liquidity

MYNZ has a Current Ratio of 0.52. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Current ratio value of 0.52, MYNZ is not doing good in the industry: 92.09% of the companies in the same industry are doing better.

MYNZ has a Quick Ratio of 0.52. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.43, MYNZ is not doing good in the industry: 92.28% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.52
Quick Ratio	0.43

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.47% over the past year.

Looking at the last year, MYNZ shows a decrease in Revenue. The Revenue has decreased by -0.17% in the last year.

The Revenue has been growing by 26.14% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)65.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%86.55%

Revenue 1Y (TTM)-0.17%

Revenue growth 3Y15.51%

Revenue growth 5Y26.14%

Sales Q2Q%-44.95%

3.2 Future

The Earnings Per Share is expected to grow by 15.04% on average over the next years. This is quite good.

Based on estimates for the next years, MYNZ will show a very strong growth in Revenue. The Revenue will grow by 133.71% on average per year.

EPS Next Y83.39%

EPS Next 2Y38.62%

EPS Next 3Y24.17%

EPS Next 5Y15.04%

Revenue Next Year-17.68%

Revenue Next 2Y-7.02%

Revenue Next 3Y32.9%

Revenue Next 5Y133.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYNZ. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MYNZ's earnings are expected to grow with 24.17% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.62%

EPS Next 3Y24.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MYNZ does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MAINZ BIOMED NV

NASDAQ:MYNZ (12/12/2025, 8:00:01 PM)

After market: 1.07 +0.04 (+3.88%)

1.03

-0.02 (-1.9%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-26 2025-09-26

Earnings (Next)03-30 2026-03-30/amc

Inst Owners5.62%

Inst Owner ChangeN/A

Ins Owners0.84%

Ins Owner ChangeN/A

Market Cap8.84M

Revenue(TTM)894.00K

Net Income(TTM)-21.65M

Analysts82.86

Price Target14.28 (1286.41%)

Short Float %4.81%

Short Ratio0.43

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)26.67%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-20.9%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	9.89
P/FCF	N/A
P/OCF	N/A
P/B	3.5
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-22.36

EYN/A

EPS(NY)-1.38

Fwd EYN/A

FCF(TTM)-1.84

FCFYN/A

OCF(TTM)-1.8

OCFYN/A

SpS0.1

BVpS0.29

TBVpS-0.17

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-220.85%
ROE	-858.34%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	64.31%
FCFM	N/A

ROA(3y)-154.86%

ROA(5y)-133.82%

ROE(3y)-451.51%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y27.49%

GM growth 5YN/A

F-Score5

Asset Turnover0.09

Health

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	27.98%
Cap/Sales	31.92%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.52
Quick Ratio	0.43
Altman-Z	-16.29

F-Score5

WACC6.07%

ROIC/WACCN/A

Cap/Depr(3y)139.31%

Cap/Depr(5y)92.63%

Cap/Sales(3y)121.7%

Cap/Sales(5y)74.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)65.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%86.55%

EPS Next Y83.39%

EPS Next 2Y38.62%

EPS Next 3Y24.17%

EPS Next 5Y15.04%

Revenue 1Y (TTM)-0.17%

Revenue growth 3Y15.51%

Revenue growth 5Y26.14%

Sales Q2Q%-44.95%

Revenue Next Year-17.68%

Revenue Next 2Y-7.02%

Revenue Next 3Y32.9%

Revenue Next 5Y133.71%

EBIT growth 1Y30.87%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y25.08%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y19.02%

OCF growth 3YN/A

OCF growth 5YN/A

MAINZ BIOMED NV / MYNZ FAQ

What is the fundamental rating for MYNZ stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYNZ.

Can you provide the valuation status for MAINZ BIOMED NV?

ChartMill assigns a valuation rating of 1 / 10 to MAINZ BIOMED NV (MYNZ). This can be considered as Overvalued.

Can you provide the profitability details for MAINZ BIOMED NV?

MAINZ BIOMED NV (MYNZ) has a profitability rating of 1 / 10.

How financially healthy is MAINZ BIOMED NV?

The financial health rating of MAINZ BIOMED NV (MYNZ) is 1 / 10.

MAINZ BIOMED NV (MYNZ) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MAINZ BIOMED NV / MYNZ FAQ

What is the fundamental rating for MYNZ stock?

Can you provide the valuation status for MAINZ BIOMED NV?

Can you provide the profitability details for MAINZ BIOMED NV?

How financially healthy is MAINZ BIOMED NV?